CGP 43371

Known as: CGP-43371, Rifamycin, N,15-didehydro-15-deoxo-1-deoxy-1,15-epoxy-3-(4-((2,4,6-trimethylphenyl)methyl)-1-piperazinyl)-, 8-(2,2-dimethylpropanoate) 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1992-2001
0119922001

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2001
2001
Ansamycins are hypolipidemic compounds which, when administered to various animal species, dramatically lower high density… (More)
Is this relevant?
1996
1996
The gastrointestinal absorption of a hypolipidemic agent (CGP 43371) was investigated using an external scintigraphy technique in… (More)
Is this relevant?
1995
1995
The ansamycins are derivatives of 3-piperazino rifamycin with potent hypolipidemic activity in nonprimate and primate species… (More)
Is this relevant?
1994
1994
The relative bioavailability of a capsule formulation and the effects of food on the pharmacokinetics of a hypolipidemic agent… (More)
Is this relevant?
1993
1993
CGP 43371 (compound I), a mono-pivaloyl oxazole derivative of a 3-piperazino-rifamycin, has been in clinical trials as a… (More)
Is this relevant?
1992
1992
The ansamycins are structurally novel hypolipidemic agents derived from rifampicin, but lacking antibacterial activity. Oral or… (More)
Is this relevant?